Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Greil

Showing results (101-110 of 145) with videos related to

Pageof 15
Sort By:
British Journal of Cancer|May 31, 2014
C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patientsK T Troppan, K Schlick, A Deutsch, et al.
Oncogene|July 7, 2010
Inhibition of GLI, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cellsP Desch, D Asslaber, D Kern, et al.
ESMO Open|March 25, 2022
Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analysis of ABCSG-18C Minichsdorfer, T Fuereder, M Leutner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2000
Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC): an AASLC phase II trial. Austrian Association for the Study of Lung CancerG Krajnik, A Mohn-Staudner, J Thaler, et al.
ESMO Gastrointestinal Oncology|April 17, 2026
Impact of nutritional risk screening on outcomes of first-line treatment in metastatic esophagogastric adenocarcinoma: a secondary analysis of the AIO-MATEO trialR Stelmach, S Lorenzen, T J Ettrich, et al.
ESMO Open|January 5, 2021
Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrenceT Magnes, S Wagner, A R Thorner, et al.
Annals of Hematology|December 24, 1997
Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor TherapyM A Fridrik, R Greil, H Hausmaninger, et al.
Leukemia|June 30, 2012
Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemiaO Merkel, N Wacht, E Sifft, et al.
Breast (Edinburgh, Scotland)|May 28, 2019
Stromal coexpression of uPA/PAI-1 protein predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancerC F Singer, M Filipits, S W Jahn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 15, 2010
Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categoriesM Fiegl, M Erdel, I Tinhofer, et al.
Pageof 15

Showing results (101-110 of 145) with videos related to

Sort By:
Pageof 15
British Journal of Cancer|May 31, 2014
C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patientsK T Troppan, K Schlick, A Deutsch, et al.
Oncogene|July 7, 2010
Inhibition of GLI, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cellsP Desch, D Asslaber, D Kern, et al.
ESMO Open|March 25, 2022
Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analysis of ABCSG-18C Minichsdorfer, T Fuereder, M Leutner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2000
Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC): an AASLC phase II trial. Austrian Association for the Study of Lung CancerG Krajnik, A Mohn-Staudner, J Thaler, et al.
ESMO Gastrointestinal Oncology|April 17, 2026
Impact of nutritional risk screening on outcomes of first-line treatment in metastatic esophagogastric adenocarcinoma: a secondary analysis of the AIO-MATEO trialR Stelmach, S Lorenzen, T J Ettrich, et al.
ESMO Open|January 5, 2021
Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrenceT Magnes, S Wagner, A R Thorner, et al.
Annals of Hematology|December 24, 1997
Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor TherapyM A Fridrik, R Greil, H Hausmaninger, et al.
Leukemia|June 30, 2012
Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemiaO Merkel, N Wacht, E Sifft, et al.
Breast (Edinburgh, Scotland)|May 28, 2019
Stromal coexpression of uPA/PAI-1 protein predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancerC F Singer, M Filipits, S W Jahn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 15, 2010
Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categoriesM Fiegl, M Erdel, I Tinhofer, et al.
Pageof 15